Literature DB >> 7127326

Phase II evaluation of bisantrene in patients with renal cell carcinoma.

J W Myers, D D Von Hoff, C A Coltman, J G Kuhn, D Van Echo, S Rivkin, R Pocelinko.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7127326

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.

Authors:  C D Haas; G W Kyle; J D Crissman; M F Schaldenbrand
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.

Authors:  G R Weiss; M Hersh; J G Kuhn; T M Ludden; D D von Hoff; D L Kisner; T E Pirtle
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Anaphylactoid reactions associated with bisantrene infusions.

Authors:  J W Myers; D D Von Hoff; J G Kuhn; C K Osborne; J F Sandbach; R Pocelinko
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer. A cancer and leukemia group B study.

Authors:  A A Forastiere; M C Perry; A K Hughes; W C Wood
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.